NICE (National Institute for Health and Clinical Excellence) stirs debate over value of medical technology in maternity
This article was originally published in Clinica
Executive Summary
The value of ensuring access to medical technology, versus its potential detrimental effect during maternity is the subject of intense debate in the UK, following last week's launch of a consultation on the subject. By the end of this year, new policy in this area will affect some 600,000 cases annually in England and Wales.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.